Added to YB: 2025-12-30
Pitch date: 2025-12-29
BXN.AX [bullish]
BLS Pharmaceuticals Limited
+126.83%
current return
Author Info
No bio for this author
Company Info
BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan.
Market Cap
AUD 213.9M
Pitch Price
AUD 0.41
Price Target
N/A
Dividend
N/A
EV/EBITDA
19.90
P/E
23.43
EV/Sales
4.41
Sector
Life Sciences Tools and Services
Category
growth
The portfolio I am taking into 2026 - Bioxyne Limited
BXN.AX: GMP-certified B2B cannabis contract manufacturer (Foxconn model) in Australia/Germany/UK. No brand/marketing risk vs other cannabis stocks. FY26 guidance: 65-75M AUD revenue, 11.5-13.5M EBITDA (115-150% YoY growth). Trading 9x PE, 6-7x EV/EBITDA.
Read full article (1 min)